Impact of B-Cell–Targeted Therapies on Cardiovascular Disease. Issue 9 (September 2019)

• Record Type: Journal Article
• Authors: Porsch, Florentina; Binder, Christoph J.
• Is Part Of: Arteriosclerosis, thrombosis, and vascular biology. Volume 39:Issue 9(2019)
• Publication Date: 2019-09
• Subjects: aneurysm -- atherosclerosis -- B-lymphocytes -- immunotherapy -- myocardial infarction; Arteriosclerosis -- Periodicals; Thrombosis -- Periodicals; Blood-vessels -- Pathophysiology -- Periodicals; Electronic journals; 616.13
• DOI: 10.1161/ATVBAHA.119.311996
• Languages: English
• ISSNs: 1079-5642

Abstract

Abstract : Atherosclerosis is a lipid-driven chronic inflammatory disease that is modulated by many immune cell subsets, including B cells. Therefore, targeting the inflammatory component of cardiovascular disease represents a promising therapeutic strategy. In the past years, immunotherapy has revolutionized the treatment of autoimmunity and cancer. Many of these clinically used strategies target B cells. Given the multifaceted role of B cells in atherogenesis, it is conceivable that B-cell–directed therapies can modulate disease development. Here, we review clinically available B-cell–targeted therapies and the possible benefits or detrimental effects on cardiovascular disease.